Breakthrough In-Office Ear Tube Solution From Tusker Medical Receives FDA Approval
04 déc. 2019 11h43 HE
|
Tusker Medical
Tula System Offers ENTs, Patients and Parents an Option Without the Operating Room Menlo Park, CA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tusker® Medical today announced United...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
07 oct. 2016 08h00 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology
18 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces FDA Approval of OTIPRIO(TM) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
11 déc. 2015 07h30 HE
|
Otonomy, Inc.
U.S. Commercial Launch Expected in the First Quarter of 2016
Webcast and Conference Call at 8:30 a.m. EST Today
SAN DIEGO, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a...
Otonomy Initiates Open-Label Clinical Trial for OTIPRIO(TM) in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
03 nov. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Host Investor and Analyst Day on October 7, 2015
30 sept. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC) will host an Investor and Analyst Day on Wednesday, October 7, 2015, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m....
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
24 sept. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere's Disease
09 sept. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints Ted Schroeder to Board of Directors
01 sept. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Second Quarter 2015 Financial Results and Provides Corporate Update
12 août 2015 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...